The Goldman Sachs Group Boosts Insmed (NASDAQ:INSM) Price Target to $196.00

Insmed (NASDAQ:INSM) had its target price boosted by analysts at The Goldman Sachs Group from $121.00 to $196.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price objective would indicate a potential upside of 24.71% from the company’s current price.

Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. upped their target price on shares of Insmed from $111.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 20th. Leerink Partners upped their target price on shares of Insmed from $100.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 10th. Bank of America upped their target price on shares of Insmed from $94.00 to $109.00 and gave the stock a “buy” rating in a research note on Wednesday, June 11th. HC Wainwright upped their target price on shares of Insmed from $90.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, June 11th. Finally, Mizuho upped their target price on shares of Insmed from $130.00 to $165.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 13th. Nineteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and an average target price of $149.06.

Insmed Price Performance

Shares of INSM opened at $157.16 on Friday. The stock has a market cap of $33.22 billion, a PE ratio of -27.52 and a beta of 1.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $158.19. The firm’s 50-day simple moving average is $132.46 and its two-hundred day simple moving average is $99.10.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million during the quarter, compared to analysts’ expectations of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.Insmed’s revenue for the quarter was up 18.9% compared to the same quarter last year. During the same quarter last year, the company posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. Analysts anticipate that Insmed will post -4.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Melvin Md Sharoky sold 10,000 shares of the firm’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the sale, the director directly owned 262,675 shares in the company, valued at $38,190,318.25. This trade represents a 3.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of Insmed stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the transaction, the insider owned 36,461 shares in the company, valued at approximately $5,303,252.45. This trade represents a 67.73% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 277,332 shares of company stock valued at $33,842,327. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

Several institutional investors have recently bought and sold shares of INSM. Cullen Frost Bankers Inc. grew its stake in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 221 shares in the last quarter. ORG Partners LLC grew its stake in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 196 shares in the last quarter. Hilltop National Bank purchased a new position in Insmed during the second quarter valued at $28,000. FNY Investment Advisers LLC purchased a new position in Insmed during the second quarter valued at $33,000. Finally, NBC Securities Inc. purchased a new position in Insmed during the first quarter valued at $49,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.